An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: Implications for hemostasis and clinical outcome

Hepatology

Volumn 58, Issue 2, 2013, Pages 752-761

  Hugenholtz, Greg C G ^a   Adelmeijer, Jelle ^a   Meijers, Joost C M ^b   Porte, Robert J ^a   Stravitz, R Todd ^c   Lisman, Ton ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; COLLAGEN; POLYMER; RISTOCETIN; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACUTE DISEASE; ACUTE LIVER FAILURE; ADULT; ARTICLE; BINDING AFFINITY; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; HEMOSTASIS; HEPATIC ENCEPHALOPATHY; HUMAN; INFECTION; KIDNEY FAILURE; LIVER INJURY; LIVER TRANSPLANTATION; MALE; MOLECULAR WEIGHT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SURVIVAL RATE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOSIS;

ACUTE LUNG INJURY; ADAM PROTEINS; ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COLLAGEN; FEMALE; HEMOSTASIS; HUMANS; LIVER FAILURE, ACUTE; MALE; MIDDLE AGED; PLATELET ADHESIVENESS; PROGNOSIS; RISK FACTORS; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 84881028718     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26372     Document Type: Article

References (34)

1. Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood 2010;116:878-885.
2. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011;365:147-156.
3. Anstee QM, Goldin RD, Wright M, Martinelli A, Cox R, Thursz MR. Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies. J Thromb Haemost 2008;6:1336-1343.
4. Villa E, Camma C, Marietta M, Luongo M, Critelli R, Colopi S, Tata C, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012;143:1253-1260.e4.
5. Lisman T, Bakhtiari K, Adelmeijer J, Meijers JC, Porte RJ, Stravitz RT. Intact thrombin generation and decreased fibrinolytic capacity in patients with acute liver injury or acute liver failure. J Thromb Haemost 2012;10:1312-1319.
6. Tripodi A, Primignani M, Chantarangkul V, Clerici M, Dell'Era A, Fabris F, et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006;44:440-445.
7. Stravitz RT, Lisman T, Luketic VA, Sterling RK, Puri P, Fuchs M, et al. Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol 2012;56:129-136.
8. Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, et al. Elevated levels of von willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006;44:53-61.
9. Ferro D, Quintarelli C, Lattuada A, Leo R, Alessandroni M, Mannucci PM, et al. High plasma levels of von willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. Hepatology 1996;23:1377-1383.
10. Albornoz L, Alvarez D, Otaso JC, Gadano A, Salviu J, Gerona S, et al. Von willebrand factor could be an index of endothelial dysfunction in patients with cirrhosis: relationship to degree of liver failure and nitric oxide levels. J Hepatol 1999;30:451-455.
11. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001;98:1662-1666.
12. George JN. Clinical practice. thrombotic thrombocytopenic purpura. N Engl J Med 2006;354:1927-1935.
13. Sadler JE. Von willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008;112:11-18.
14. Wright M, Goldin R, Hellier S, Knapp S, Frodsham A, Hennig B, et al. Factor V leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut 2003;52:1206-1210.
15. Ferlitsch M, Reiberger T, Hoke M, Salzl P, Schwengerer B, Ulbrich G, et al. Von willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology 2012;56:1439-1447.
16. Takaya H, Uemura M, Fujimura Y, Matsumoto M, Matsuyama T, Kato S, et al. ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the Child-Turcotte-Pugh score and the model for end-stage liver disease score. Hepatol Res 2012;42:459-472.
17. La Mura V, Reverter JC, Flores-Arroyo A, Raffa S, Reverter E, Seijo S, et al. Von willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. Gut 2011;60:1133-1138.
18. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439-445.
19. Conn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Maddrey WC, Seeff L, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977;72:573-583.
20. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-874.
21. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005;129:93-100.
22. Lisman T, Moschatsis S, Adelmeijer J, Nieuwenhuis HK, De Groot PG. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood 2003;101:1864-1870.
23. Wells AW, Llewelyn CA, Casbard A, Johnson AJ, Amin M, Ballard S, et al. The EASTR study: indications for transfusion and estimates of transfusion recipient numbers in hospitals supplied by the national blood service. Transfus Med 2009;19:315-328.
24. Crawley JT, Lam JK, Rance JB, Mollica LR, O'Donnell JS, Lane DA. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood 2005;105:1085-1093.
25. Reiter RA, Knobl P, Varadi K, Turecek PL. Changes in von willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin. Blood 2003;101:946-948.
26. Bonnefoy A, Legrand C. Proteolysis of subendothelial adhesive glycoproteins (fibronectin, thrombospondin, and von willebrand factor) by plasmin, leukocyte cathepsin G, and elastase. Thromb Res 2000;98:323-332.
27. Chen J, Reheman A, Gushiken FC, Nolasco L, Fu X, Moake JL, et al. N-acetylcysteine reduces the size and activity of von willebrand factor in human plasma and mice. J Clin Invest 2011;121:593-603.
28. Bongers TN, de Bruijne EL, Dippel DW, de Jong AJ, Deckers JW, Poldermans D, et al. Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients. Atherosclerosis 2009;207:250-254.
29. Martin K, Borgel D, Lerolle N, Feys HB, Trinquart L, Vanhoorelbeke K, et al. Decreased ADAMTS-13 (a disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure. Crit Care Med 2007;35:2375-2382.
30. Lowenberg EC, Charunwatthana P, Cohen S, Van Den Born BJ, Meijers JC, Yunus EB, et al. Severe malaria is associated with a deficiency of von willebrand factor cleaving protease, ADAMTS13. Thromb Haemost 2010;103:181-187.
31. Djamiatun K, van der Ven AJ, de Groot PG, Faradz SM, Hapsari D, Dolmans WM, et al. Severe dengue is associated with consumption of von willebrand factor and its cleaving enzyme ADAMTS-13. PLoS Negl Trop Dis 2012;6:e1628.
32. Anstee QM, Wright M, Goldin R, Thursz MR. Parenchymal extinction: coagulation and hepatic fibrogenesis. Clin Liver Dis 2009;13:117-126.
33. Calvaruso V, Maimone S, Gatt A, Tuddenham E, Thursz M, Pinzani M, et al. Coagulation and fibrosis in chronic liver disease. Gut 2008;57:1722-1727.
34. Ganey PE, Luyendyk JP, Newport SW, Eagle TM, Maddox JF, Mackman N, et al. Role of the coagulation system in acetaminophen-induced hepatotoxicity in mice. Hepatology 2007;46:1177-1186.